RWM
PACB icon

Rialto Wealth Management’s Pacific Biosciences PACB Stock Holding History

Rialto Wealth Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-385
Closed -$455 – 1749
2025
Q1 		$455 Buy
+385
New +$591 ﹤0.01% 936

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rialto Wealth Management's PACB Position: Q2 2025 in Review

Rialto Wealth Management sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 385 shares — an estimated $455 sold.

Rialto Wealth Management first reported a position in PACB in Q1 2025 and held it in 1 quarter. The position peaked at $455 in Q1 2025. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • Rialto Wealth Management reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • Rialto Wealth Management sold 385 Pacific Biosciences shares in Q2 2025, an estimated $455.
  • Rialto Wealth Management first reported a position in Pacific Biosciences in Q1 2025 and held it in 1 quarter.
  • Rialto Wealth Management's Pacific Biosciences position peaked at $455 in Q1 2025.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Rialto Wealth Management's 13F filing for Q2 2025, filed 6 Aug 2025.